Details of the Drug

General Information of Drug (ID: )

• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw)
  Logarithm of the Partition Coefficient (xlogp)
  Rotatable Bond Count (rotbonds)
  Hydrogen Bond Donor Count (hbonddonor)
  Hydrogen Bond Acceptor Count (hbondacc)
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 145-228 mgh/L [1]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 26.1 mg/L [1]
  Bioavailability: The bioavailability of drug is 34-58% [1]
  Clearance: The clearance of drug is 8.8 L/h [2]
  Elimination: Approximately 59% of selumetinib is eliminated in the feces, while 33% is eliminated in the urine [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 6.2 hours (in pediatric patients) [4]
  Metabolism: The drug is metabolized via the liver [3]
  Vd: The volume of distribution (Vd) of drug is 78-171 L [2]

References

• [1] Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ: Fosfomycin. Clin Microbiol Rev. 2016 Apr;29(2):321-47. doi: 10.1128/CMR.00068-15.
• [2] FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use
• [3] Smith JP, Weller S, Johnson B, Nicotera J, Luther JM, Haas DW: Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 2010 Mar;54(3):1146-51. doi: 10.1128/AAC.00729-09. Epub 2009 Dec 28.
• [4] Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. Jpn J Clin Oncol. 2018 Jan 1;48(1):31-42. doi: 10.1093/jjco/hyx144.